Immix Biopharma, Inc.

Stage 2 · Advancing · week 10

As of Oct 22, 2026, Immix Biopharma is in Stage 2, the uptrend phase, now in week 10 (since Aug 14, 2026). It closed at $8.35, 42.3% below its 52-week high and below its 200-day average, which is rising.

$8.35

-2.34% today

$692M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is IMMX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 20w

S4 36w

S2 13w

S2 32w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 1w → S2 1w → S3 3w → S2 20w → S3 6w → S4 36w → S1 6w → S2 5w → S3 2w → S4 9w → S1 3w → S2 13w → S3 7w → S2 32w → S3 5w → S2 4w → S3 1w → S2 10w current

Total tracked: 164 weeks across 18 stage runs.

IMMX among Biotechnology26th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…26	IMMXImmix Biopharma, Inc.	Stage 2 · wk 10	97	−29.9%

vs 52W High

-42.3%

$3.03 lo$14.47 hi

42.3% below 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 10

1w13w26w

Week 10, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-11.0%

200 DMA: $9.39 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.52x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-29.9%

-2.0%

-17.9%

YTD

+53.8%

+162.6%

Scan Membership

Breakout Watch

Latest: 2025-06-02

7 appearances in last 60 days. First seen: 2023-01-31.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 10 · Vol 0.52x

2026-10-21S2

Wk 10 · Vol 0.80x

2026-10-20S2

Wk 10 · Vol 0.77x

2026-10-19S2

Wk 10 · Vol 0.81x

2026-10-16S2

Wk 9 · Vol 0.94x

2026-10-15S2

Wk 9 · Vol 0.83x

2026-10-14S2

Wk 9 · Vol 0.85x

2026-10-13S2

Wk 9 · Vol 0.92x

2026-10-12S2

Wk 9 · Vol 0.58x

2026-10-09S2

Wk 8 · Vol 0.68x

2026-10-08S2

Wk 8 · Vol 0.79x

2026-10-07S2

Wk 8 · Vol 0.85x

Moving averages & range

50 DMA

$11.49

200 DMA

$9.39

52W High

$14.47

52W Low

$3.03

5D Low

$7.98

Resistance levels (recent highs)

20d High

$11.47

60d High

$14.47

120d High

$14.47

250d High

$14.47

Next resistance

+37.4%

to 20d High

ROE

-34.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.6

Immix Biopharma: quick answers

What stage is Immix Biopharma in?

As of Oct 22, 2026, Immix Biopharma (IMMX) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 14, 2026 and is in week 10. What the four stages mean

Is Immix Biopharma in an uptrend?

Yes. Immix Biopharma is in a Stage 2 uptrend. It trades 11.0% below its 200-day average, which is rising.

How far is Immix Biopharma from its 52-week high?

Immix Biopharma closed at $8.35 on Oct 22, 2026, 42.3% below its 52-week high of $14.47. Its 52-week low is $3.03.

How has Immix Biopharma performed over the past year?

As of Oct 22, 2026, Immix Biopharma is up 162.6% over the past year and up 53.8% so far in 2026.

Which sector and industry is Immix Biopharma in?

Immix Biopharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.